MarketPulse

equity offering

9 articles
BenzingaBenzinga··Lekha Gupta

Velo3D Shares Plunge 18% on $50M Equity Offering Despite Strong Uptrend

Velo3D shares fell 18.32% after announcing a $50M equity offering at $14 per share, though analysts maintain Buy ratings and the stock remains up 416.67% over 12 months.
VELOtechnical analysisequity offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zenas BioPharma Raises $300M Through Convertible Notes and Stock Offering

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.
ZBIOautoimmune diseasesequity offering
BenzingaBenzinga··Globe Newswire

Datacentrex Prices $20.17M Share Offering at $2.00 Per Share

Datacentrex prices confidential offering of 10.085M shares at $2.00 each, raising $20.17M for working capital and corporate purposes.
DTCXequity offeringpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Datacentrex Raises $20.17M via CMPO at $2.00 Share Price

Datacentrex prices $20.17M offering at $2.00 per share, closing March 30, 2026. Proceeds support working capital and general corporate needs.
DTCXequity offeringpublic offering
The Motley FoolThe Motley Fool··Jonathan Ponciano

Apogee CEO Sells $1.5M in Stock Despite 100% Surge; Clinical Data Tells Real Story

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sol-Gel Raises $33.1M via Oversubscribed Offering to Advance Rare Disease Pipeline

Sol-Gel Technologies prices 459,112 shares at $72 each, raising $33.1M for SGT-610 development in Gorlin syndrome treatment.
SLGLPhase 3 clinical trialequity offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus Therapeutics Raises $625M in Upsized IPO Offering to Fund Pipeline Expansion

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.
DNTHbiotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Alx Oncology Holdings Inc.

ALX Oncology Narrows Losses, Secures Funding as Clinical Pipeline Advances

ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.
ALXOclinical trialsevorpacept
BenzingaBenzinga··Lekha Gupta

JIADE Limited Launches $3M Direct Equity Offering

JIADE Limited launches $3M direct equity offering of 12M shares at $0.25 each. Stock fell 8.13% on announcement; potential $12M if all options exercised.
JDZGstock declineequity offering